About our project

The problem we solve: Solid tumors represent 90% of the newly diagnosed cases, and the vast majority have >50% mortality rates due to aggressive relapse that current therapies cannot effectively address. Among all solid tumors, pancreatic cancer has one of the highest patient mortality killing over 80% of patients in the US and over 90% patients globally each year within 2 years of diagnosis. Furthermore, the extremely high price tag of current cell therapy products makes development of effective cell therapy approaches against pancreatic cancer unaffordable, ultimately hurting the chances of a successful disease remission in the cancer patients.

About our solution: Immumem's scalable and affordable allogeneic iPSC-derived cell therapy addresses immune cell exhaustion and tumor relapse, major contributors to high mortality rates. With 2-5x better tumor control and 5-10x better relapse control compared to existing therapies, our first product, IMT-101 generated using our proprietary platform targets pancreatic cancer using iPSC-derived memory CAR-T and CAR-NK cells. These cells possess enhanced tumor infiltration, mitigate antigen escape, and minimize allorejection, leading to a sustained remission in the patients. Furthermore, the cost associated with the production of each dose of our product will be at least 10 times lesser than the current autologous and allogeneic cell therapy approaches; thereby significantly increasing the accessibility and affordability of our product to a broad patient population.

Progress to date:

Immumem has developed an alpha platform to test out the potency of immunological memory in fighting cancer relapse. Early data showed that the alpha version of our cell therapy product demonstrated 2-5 times better tumor control and 5-10 times better relapse control against solid tumors compared to existing therapies. This has not only soft-circled angel investors but has led several VC that invest in late-stage biotech companies to seek investment in us once we reach the clinical trial stage for our product targeting pancreatic cancer. We are also on track to securing $100,000 in non-dilutive funding and have at least 4 patents in our pipeline.

About Our Company

How We Help Patients

Immumem's allogeneic iPSC-derived cell therapy offers transformative benefits for pancreatic cancer patients. By increasing solid tumor infiltration and enhancing tumor killing and persistence, this therapy significantly improves outcomes compared to traditional treatments. The product selectively targets and eliminates cancer cells, reducing collateral damage to healthy tissue associated with radiotherapy and chemotherapy. This leads to fewer side effects, such as nausea, fatigue, and organ damage, allowing patients to maintain a better quality of life.

The therapy can minimize the need for invasive surgical resection, sparing patients from prolonged recovery and complications. While checkpoint inhibitors have shown limited efficacy in pancreatic cancer, the enhanced persistence of Immumem's product can provide more durable responses, reducing the risk of relapse and the need for repeated treatments.

Patients experience increased disease remission and higher five-year survival rates, leading to longer, healthier lives. The therapy's affordability, being at least five times cheaper than existing cell therapies, and its increased accessibility to a wider patient population further enhance its impact.

Diversified revenue streams from commercialization will ensure financial sustainability for ongoing research and global distribution, facilitating continuous improvement and broader reach. This innovative approach not only extends lifespan but also significantly improves the quality of life for pancreatic cancer patients by offering a more effective and less invasive treatment option.

How We Help Physicians

Improved Treatment Outcomes: The enhanced features of this cell therapy, such as increased solid tumor infiltration, sustained immunological memory, and reduced antigen escape, can lead to better treatment outcomes for patients. Physicians will be able to offer their patients a more effective therapy option that can extend survival and improve quality of life, which is a significant unmet need in pancreatic cancer.

Reduced Adverse Effects: The targeted nature of the cell therapy, which minimizes collateral damage to healthy tissues, can result in fewer adverse effects compared to traditional treatments like chemotherapy and radiation. This allows physicians to prescribe a therapy that is better tolerated by patients, reducing the need to manage and mitigate severe side effects, and enabling patients to better adhere to the treatment regimen.

Expanded Treatment Options: For physicians, the availability of this innovative cell therapy provides an additional treatment modality in their arsenal against pancreatic cancer. Given the limited efficacy of current immunotherapies like checkpoint inhibitors in this disease, the cell therapy offers a new approach that can benefit patients who have exhausted or are ineligible for other standard-of-care options.

Reduced Treatment Burden: By minimizing the need for invasive surgical resection and potentially reducing the frequency of repeated treatments, the cell therapy can help alleviate the treatment burden on both the patient and the healthcare system. Physicians can focus on optimizing the use of this targeted therapy rather than having to coordinate complex multi-modal treatment regimens.

Improved Practice Efficiency: The affordability and increased accessibility of the cell therapy can enable more physicians to offer this treatment option to their patients. This, in turn, can improve the efficiency of their practice by providing a viable, cost-effective alternative to existing cell therapies, which often have high associated costs and limited availability.

How We Help Hospitals

Improved Patient Outcomes and Reduced Costs: The enhanced efficacy of our products can lead to better patient outcomes. This translates to reduced hospitalizations, fewer complications, and lower overall treatment costs for the healthcare institution. Fewer adverse events and a better quality of life for patients also mean reduced resource utilization and cost savings.

Expanded Treatment Options and Specialty Care: The availability of this novel cell therapy provides an additional treatment modality for healthcare organizations in their arsenal against pancreatic cancer. Given the limited efficacy of current immunotherapies in this disease, the cell therapy offers a new approach that can benefit patients who have exhausted or are ineligible for other standard-of-care options. This can help position the institution as a specialty center for advanced cancer treatments.

Improved Patient Satisfaction and Retention: By offering a more effective and better-tolerated treatment option, hospitals and medical centers can improve patient satisfaction and retention. Patients are more likely to continue their care at an institution that can provide innovative, cutting-edge therapies that offer the prospect of better outcomes and quality of life.

Enhanced Reputation and Competitiveness: The successful implementation of this transformative cell therapy can enhance the reputation and competitiveness of the healthcare institution. Being able to offer this advanced treatment option can attract more patients, improve referrals from other providers, and solidify the institution's standing as a leader in cancer care.

Financial Sustainability and Revenue Diversification: The affordability of Immumem's allogeneic iPSC-derived cell therapy can significantly benefit hospitals by increasing insurance payouts and Medicare/Medicaid coverage. The therapy's cost-effectiveness, being at least five times cheaper than existing cell therapies, allows hospitals to demonstrate its value in terms of improved patient outcomes at a lower overall cost. This affordability can expand access to a wider patient population, leading to more insurance claims and higher reimbursement volumes. Additionally, the therapy's alignment with cost-containment initiatives by healthcare payers, the reduced financial strain on hospitals, and the potential for favorable reimbursement policies further incentivize the adoption and coverage of this innovative, high-impact treatment. Furthermore, the affordability of our therapy can also help overcome the cost barriers that often prevent smaller or less-resourced healthcare organizations from adopting novel, high-cost treatments. The reduced financial burden can enable these facilities to offer this innovative therapy to their patient populations.

Improved Accessibility To Underutilized Healthcare Organizations: The "off-the-shelf" nature of our allogeneic cell therapy, as opposed to autologous therapies that require personalized manufacturing, will allow for easier distribution and access to healthcare organizations in remote or underserved areas. These facilities, often lacking the specialized infrastructure and resources required for complex autologous cell therapies, can readily obtain and administer our pre-manufactured allogeneic product.

Reduced Logistical Challenges: Current autologous cell therapies typically involve complex logistics, including cell collection, transportation to a manufacturing facility, and then the return of the personalized product to the treatment site. This complex supply chain is a significant barrier, especially for smaller or less-resourced healthcare organizations. The allogeneic approach of our product simplifies the logistics, as the ready-to-use cell therapy doses can be shipped directly to the treatment site, reducing the burden on the healthcare provider.

Faster Time to Treatment: With autologous cell therapies, the time required for manufacturing the personalized product can significantly delay the initiation of treatment, which is particularly critical for patients with aggressive cancers like pancreatic cancer. The availability of our allogeneic cell therapy, which can be immediately administered upon delivery, can greatly accelerate the time to treatment, ensuring patients receive the critical therapy sooner and potentially improving outcomes.

How We Help Partners

Our innovative allogeneic iPSC-derived cell therapy can provide significant benefits to potential partners, helping them address real problems and achieve greater success.

Expanded Treatment Portfolio: For pharmaceutical companies and other healthcare industry players, Immumem's cell therapy offers an opportunity to expand their treatment portfolio and provide a new, differentiated therapy option for pancreatic cancer patients. This can help partners diversify their product offerings and better cater to the unmet needs in this disease area.

Improved Patient Outcomes: The enhanced features of Immumem's cell therapy, such as increased solid tumor infiltration, sustained immunological memory, and reduced antigen escape, can lead to better treatment outcomes for patients. Partnering with Immumem allows these industry players to offer a more effective therapy, which can translate to improved patient satisfaction and stronger brand reputation.

Accelerated Time to Market: Rather than investing in the lengthy and resource-intensive process of developing a proprietary cell therapy, big pharma and other industry players in the biotech sector can leverage Immumem's ready-to-go product and benefit from a faster path to market. This can help them quickly address the urgent need for innovative treatments in pancreatic cancer and gain a competitive advantage.

Shared Risk and Reward: By entering into a strategic partnership with Immumem, industry players can share the risks and costs associated with bringing a novel cell therapy to market, while also participating in the potential rewards and revenue streams. 

Increased Demand and Revenue Streams: As Immumem's cell therapy gains market traction and adoption, the CDMO will benefit from the increased demand for GMP-compliant manufacturing services. This can translate to a steady and potentially growing revenue stream for the CDMO, diversifying its business and improving financial sustainability.

Immumem can make its partners more successful by demonstrating the clinical and commercial viability of its cell therapy through pilot programs and partnerships. This can help partners satisfy their pain points, such as the need for more effective treatments, faster time to market, and reduced operational complexities. By addressing these real problems, Immumem can position itself as a valuable collaborator and unlock the support of key healthcare industry players, further accelerating the adoption and impact of its transformative therapy.

Innovation Details

Intellectual Property Summary

Currently a trade secret since we have revealed none of our 'secret sauce' to anyone outside the organization yet. However, we have 4 patents in the pipeline that we are in the process of filing to strengthen the protection of our intellectual property and talk more freely about our data and strategies involved.

Clinical Information

Currently in the preclinical stages of product developement. We expect to reach the clinical development stage of our product in next 2-4 years and enter the conventional IND filing process needed to begin phase I clinical trial on our product.

Regulatory Status

Currently in pre-IND stage, so FDA clearance is not applicable to us. Our FDA clearance plan entails begining CMC processes after 2 years and begin IND-enabling activities required to get FDA approval to begin clinical trials in the following 2 years or so.

How we will use the funds raised

Labspace leasing and instruments: $100K

R&D studies: $200K

Intellectual property-related filings: $50K

Thank You

Pancreatic cancer is one of the most devastating and deadly forms of cancer. With a 5-year survival rate of less than 10%, it kills more than 80% of patients annually due to a severe lack of effective treatment options. Immumem Therapeutics is working to change that.

Immumem Therapeutics is a biotech company dedicated to developing innovative cell-based therapies to treat this deadly disease. Their researchers have made promising progress in creating a novel approach that harnesses the power of the immune system to target and eliminate pancreatic cancer cells, including those that drive relapse.

This pioneering cell therapy has the potential to dramatically improve outcomes for pancreatic cancer patients. However, bringing a new treatment from the lab to the clinic requires significant resources. That's why Immumem Therapeutics is launching a critical $350,000 fundraising campaign.

The funds raised will enable Immumem to advance this cell therapy through preclinical studies and prepare for human clinical trials. This is a crucial next step to demonstrate the therapy's safety and efficacy, and ultimately make it available to patients who desperately need new treatment options.

Pancreatic cancer is a formidable foe, but together we can give hope to those affected. Your support can make a real difference in the fight against this deadly disease.

Please consider making a donation to Immumem Therapeutics today. Every contribution, no matter the size, will help drive progress toward a viable and affordable cell therapy that could save lives.

Time is of the essence for pancreatic cancer patients. With your help, Immumem Therapeutics can accelerate its research and bring this transformative cell therapy one step closer to the patients who need it most.

Join us in the mission to confront and conquer pancreatic cancer. Donate now and be part of the solution.

Investor Info

Market Size

The anticipated market size for our first product, IMT-101, focusing on pancreatic cancer treatment, is approximately $3billion/year. This figure is derived from an estimated 20,206 new cases of pancreatic cancer diagnosed every year in the U.S. who have failed atleast one line of treatment and are currently living with relapsed disease since 2021. Given the expected cost of IMT-101 at $150,000 per patient, this translates to a Serviceable Obtainable Market (SOM) of $3 billion/year.

In terms of Total Market Opportunity (TAM) and Serviceable Available Market (SAM), our figures are as follows:

• Total Addressable Market (TAM): $38 billion per year
• Serviceable Available Market (SAM): $16 billion per year

The SAM was calculated based on the percentages of patients receiving second-line treatments across various cancer types, including pancreatic cancer (38% from the TAM) and other cancers such as colorectal (45%), ovarian (56%), and cervical (12.2%). For the SOM of IMT-101, we focused specifically on pancreatic cancer patients, estimating that 80% of the SAM has undergone at least one prior treatment.

The market is projected to grow at a compound annual growth rate (CAGR) of 22.66% by 2030, indicating significant expansion potential driven by advances in cancer therapies and increasing patient needs.

For reference, please see:

-seer.cancer.gov/statfacts/html/pancre.html

-doi.org/10.1007/s12325-022-02317-9

-doi.org/10.21873/anticanres.13952

-www.grandviewresearch.com/industry-analysis

Projected 3 Year Growth

Following the BLA approval of IMT-101 by FDA, market penetration for cell therapy drugs targeting cancer within the first 3 years can vary depending on various factors such as the specific cancer type, competition, and regulatory approvals. However, based on industry trends and data from similar therapies, a typical market penetration within the first 3 years can range from 5% to 10% of the total addressable market (TAM). This estimation takes into account the time required for clinical trials, regulatory approvals, and the gradual adoption of the therapy by healthcare providers and patients. Assuming cell therapy drugs targeting pancreatic cancer will have a total addressable market of 66,440 cases per year and a more conservative estimate of market penetration of 1% for cell therapy drugs in the first 3 years, the estimated market penetrationof IMT-101 is approximately 664 patients per year. This calculation is based on the current data on market penetration for cell therapy products against hematological malignancies and immune checkpoint inhibitors against pancreatic cancer.

That being said, considering the cost of producing each dose at $25,000, patient acquisition cost per dose at $10,000 (this includes marketing, sales, and other costs to acquire each patient) and the price tag of each dose at $150,000, the gross profit margin will sit around 76%. This high gross margin is typical for novel cell therapy and biologics products targeting cancer, where the value proposition and pricing power allows for significant profitability. This will amount to a very conservative annual revenue of $99.6 million/year and an annual gross profit of $76.3 million/year during the first 3 years. This will be the profit margin despite selling our product at a price that is at least 5 times cheaper than the typical price tag for currently available cell therapy options in the market. 

References:

-https://doi.org/10.1038/d41573-019-00014-x

-https://doi.org/10.1001/jamaoncol.2019.2187

-https://icer.org/assessment/cemiplimab-2019/

-https://www.grandviewresearch.com/industry-analysis/cell-therapy-market

-doi.org/10.1080/20016689.2019.1660143

-http://www.cbinsights.com/research/report/patient-acquisition-costs-specialty-drugs/

Revenue Model

Before BLA Approval, our products can generate significant revenue from collaborations with large pharmaceutical (big pharma) companies. These revenue streams include upfront cash payments for collaboration agreements, equity investment agreements, milestone payments for reaching development and regulatory milestones, and royalty payments for offering exclusive marketing rights. The total estimated revenue from big pharma collaborations before BLA approval is around $284 million per year.

After BLA approval, our products can continue to generate revenue from ongoing big pharma collaborations, such as additional milestone payments and royalty payments. However, the largest revenue streams are expected to come from cancer patients and foreign biotech companies. From cancer patients, cell therapy companies can generate revenue through insurance reimbursements, government programs like Medicaid and Medicare, and out-of-pocket payments from patients. The total estimated revenue from cancer patients after BLA approval is around $3 billion per year. Additionally, Immumem can generate substantial revenue from international licensing agreements with foreign biotech companies, who will pay a percentage of the revenue generated through sales within their domestic markets. The total estimated revenue from foreign biotech companies after BLA approval is around $5.1 billion per year.

References:

-https://doi.org/10.1038/d41573-019-00014-x

-https://doi.org/10.1016/j.ctrv.2018.02.004

-https://doi.org/10.1001/jamaoncol.2019.2187

-https://icer.org/assessment/cemiplimab-2019/

Competitors

Fate Therapeutics, Century Therpaeutics, Shoreline Biosciences, HebeCell Corp, Caribou Biosciences, Genentech, Kite Pharma and Poseida.

We believe our approach will hold an edge over our competitors because it uniquely addresses seven major challenges hindering the effectiveness of their approaches such as:

1. Overcoming the impenetrable tumor extracellular matrix by immune cells.

2. Mitigating tumor-mediated hypoxia and acidosis-induced immune exhaustion and drastically improving tumor killing capability and in vivo persistence.

3. Preventing antigen escape by the heterogenous tumor sub-populations.

4. Avoiding allorejection by the patient immune system.

5. Minimizing off-tumor side effects through logic-gated CAR expression.

6. Scaling up and de-complexing the iPSC differentiation and manufacturing protocols in a capital efficient manner; driving down cost per each dose by at least 5 times.

7. Furthermore, our strategy will avoid dependence on often-compromised patient immune systems that the current immunotherapy products utilize.

Traction

Potential customers: Big pharma companies, cancer patients and foreign biotech companies

Due Diligence Docs

Please note that access to the company's confidential materials is limited. Click this button to request access from the Company and its representatives.

Send access request

Supporters

• 
  Mr. Alex Fair, MS
  03/24/2025 - Liked the project.
• 
  Mr. Alex Fair, MS
  03/24/2025 - Followed the project.
• 
  Mr. Alex Fair, MS
  03/24/2025 - Interested in investing in the project.
• 
  Dr. Shubh Gupta, PhD
  03/24/2025 - Liked the project.

Comments

Updates

No updates found .